Epstein-Barr virus (EBV) association and latency profile in pediatric Burkitt's lymphoma: Experience of a single institution in Argentina

Journal of Medical Virology

Volumn 86, Issue 5, 2014, Pages 845-850

  Lara, Julia ^a   Cohen, Melina ^a   De Matteo, Elena ^a   Aversa, Luis ^a   Preciado, Maria Victoria ^a   Chabay, Paola ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

BHRF1; Childhood; EBV; Latency; LMP1; Lymphoma

Indexed keywords

CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 6;

ADOLESCENT; ANTIGEN EXPRESSION; ARGENTINA; ARTICLE; BONE MARROW; BURKITT LYMPHOMA; CELL MEMBRANE; CERVICAL LYMPH NODE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; ILEOCECAL VALVE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; MALE; MEDIASTINUM; ONCOGENE C MYC; OVARY; PRESCHOOL CHILD; PROMOTER REGION; SCALP; SCHOOL CHILD; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

BHRF1; CHILDHOOD; EBV; LATENCY; LMP1; LYMPHOMA;

ADOLESCENT; ARGENTINA; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL PROTEINS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84895927085     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23737     Document Type: Article

References (21)

1. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB. 2006. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87:2885-2890.
2. Brady G, MacArthur GJ, Farrell PJ. 2007. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 60:1397-1402.
3. Carbone A, Gloghini A, Dotti G. 2008. EBV-associated lymphoproliferative disorders: Classification and treatment. Oncologist 13:577-585.
4. Chabay P, Burna V, Moar A, Grinstein S, Preciado MV. 1999. Prevalencia de la infección por el virus de Epstein-Barr en pacientes pediátricos. Rev Hosp De Niños B Aires 41:88-91.
5. Chabay PA, Barros MH, Hassan R, De Matteo E, Rey G, Carrico MK, Renault IZ, Preciado MV. 2008. Pediatric Hodgkin lymphoma in 2 South American series: A distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol 30:285-291.
6. Fritsch MK, Bridge JA, Schuster AE, Perlman EJ, Argani P. 2003. Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatr Dev Pathol 6:43-53.
7. God JM, Haque A. 2010. Burkitt lymphoma: Pathogenesis and immune evasion. J Oncol 2010:1-14.
8. Gutiérrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueño C, Magrath IT. 1992. Molecular epidemiology of Burkitt's lymphoma from South America: Differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 79:3261-3266.
9. Hassan R, Klumb CE, Felisbino FE, Guiretti DM, White LR, Stefanoff CG, Barros MH, Seuánez HN, Zalcberg IR. 2008. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in Southeastern Brazil: Epidemiological insights from an intermediate risk region. Haematologica 93:780-783.
10. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 25:587-617.
11. Kelly G, Rickinson A. 2007. Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007:277-284.
12. Kennedy G, Komano J, Sugden B. 2003. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100:14269-14274.
13. Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, Harrington WJ, Jr., Bacchi CE. 2008. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol 130:946-956.
14. Rao CR, Gutierrez MI, Bhatia K, Fend F, Franklin J, Appaji L, Gallo G, O'Conor G, Lalitha N, Magrath I. 2000. Association of Burkitt's lymphoma with the Epstein-Barr virus in two developing countries. Leuk Lymphoma 39:329-337.
15. Registro Oncopediátrico Argentino. Resultados 2000-2008. Available at: http://www.roha.org.ar. Accessed May 10, 2012.
16. Rowe M, Kelly GL, Bell AI, Rickinson AB. 2009. Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19:377-388.
17. Seifert M, Scholtysik R, Küppers R. 2013. Origin and pathogenesis of B cell lymphomas. Methods Mol Biol 971:1-25.
18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: IARC Press.
19. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. 1998. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue. Blood 91:1373-1381.
20. Thorley-Lawson DA, Allday MJ. 2008. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6:913-924.
21. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe P, Molyneux E, Broadhead RL, Borgstein E, Griffin BE. 2002. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99:635-643.